VIVOPLEX

VIVOPLEX is an in-situ immunotherapy platform developed by Traverse Biotech. The technology is designed to be administered directly into a tumor (intratumoral injection) to modulate the local immune environment, thereby promoting the recognition of tumor-associated antigens and the activation of a systemic immune response. This approach, often referred to as 'in-situ vaccination,' aims to treat both the injected primary tumor and distant, non-injected metastatic lesions (the abscopal effect). As a platform technology, VIVOPLEX serves as a foundation for various oncology programs, though specific targets and clinical phases for individual candidates have not been publicly detailed.

Brand names

VIVOPLEX